Biomerica (BMRA) Competitors $0.54 -0.03 (-5.26%) As of 12:03 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. VRPX, XFOR, CTOR, VNRX, AADI, HOWL, IMMX, IPSC, ITRM, and OTLKShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Virpax Pharmaceuticals (VRPX), X4 Pharmaceuticals (XFOR), Citius Oncology (CTOR), VolitionRx (VNRX), Aadi Bioscience (AADI), Werewolf Therapeutics (HOWL), Immix Biopharma (IMMX), Century Therapeutics (IPSC), Iterum Therapeutics (ITRM), and Outlook Therapeutics (OTLK). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Virpax Pharmaceuticals X4 Pharmaceuticals Citius Oncology VolitionRx Aadi Bioscience Werewolf Therapeutics Immix Biopharma Century Therapeutics Iterum Therapeutics Outlook Therapeutics Biomerica (NASDAQ:BMRA) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, community ranking, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment. Which has more volatility & risk, BMRA or VRPX? Biomerica has a beta of -1.17, meaning that its stock price is 217% less volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Do insiders & institutionals believe in BMRA or VRPX? 22.3% of Biomerica shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 15.0% of Biomerica shares are held by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer BMRA or VRPX? In the previous week, Virpax Pharmaceuticals had 1 more articles in the media than Biomerica. MarketBeat recorded 1 mentions for Virpax Pharmaceuticals and 0 mentions for Biomerica. Biomerica's average media sentiment score of 0.49 beat Virpax Pharmaceuticals' score of 0.00 indicating that Biomerica is being referred to more favorably in the media. Company Overall Sentiment Biomerica Neutral Virpax Pharmaceuticals Neutral Does the MarketBeat Community believe in BMRA or VRPX? Biomerica received 134 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 67.82% of users gave Biomerica an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBiomericaOutperform Votes13767.82% Underperform Votes6532.18% Virpax PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% Is BMRA or VRPX more profitable? Virpax Pharmaceuticals has a net margin of 0.00% compared to Biomerica's net margin of -100.52%. Biomerica's return on equity of -90.19% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-100.52% -90.19% -64.54% Virpax Pharmaceuticals N/A -1,554.34%-338.29% Do analysts prefer BMRA or VRPX? Virpax Pharmaceuticals has a consensus price target of $75.00, indicating a potential upside of 6,047.54%. Given Virpax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Virpax Pharmaceuticals is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings and valuation, BMRA or VRPX? Biomerica has higher revenue and earnings than Virpax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.58M1.87-$5.98M-$0.34-1.67Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A SummaryBiomerica beats Virpax Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Remove Ads Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.43M$2.45B$5.58B$7.92BDividend YieldN/A0.74%5.35%4.04%P/E Ratio-1.676.2423.0918.81Price / Sales1.8742.89366.7388.86Price / CashN/A15.7538.1634.64Price / Book1.462.996.694.18Net Income-$5.98M-$65.73M$3.20B$247.10M7 Day Performance-8.13%-3.66%-3.92%-2.74%1 Month Performance-20.16%-9.59%1.69%-3.92%1 Year Performance-31.84%-24.48%8.33%-0.12% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.6587 of 5 stars$0.54-5.3%N/A-33.5%$9.88M$5.58M-1.5860Upcoming EarningsVRPXVirpax Pharmaceuticals1.6009 of 5 stars$1.94-6.3%$3.00+54.6%-98.8%$51.53MN/A0.007Positive NewsGap DownXFORX4 Pharmaceuticals4.4731 of 5 stars$0.30-4.0%$3.50+1,086.4%-83.5%$51.23M$1.12M-3.2880Analyst RevisionCTORCitius OncologyN/A$0.71+14.5%$3.00+322.5%N/A$50.80MN/A0.00N/AGap DownVNRXVolitionRx2.0112 of 5 stars$0.55-0.4%$3.75+584.3%-30.2%$50.78M$1.29M-1.5280Analyst ForecastGap DownAADIAadi Bioscience1.1086 of 5 stars$2.05+4.6%$1.67-18.7%-22.0%$50.63M$25.07M-0.9040Positive NewsHOWLWerewolf Therapeutics1.981 of 5 stars$1.12-0.9%$9.00+703.6%-84.9%$50.21M$1.89M-0.7340Gap DownIMMXImmix Biopharma2.9254 of 5 stars$1.82+1.1%$7.00+284.6%-43.9%$50.07MN/A-2.149News CoveragePositive NewsGap DownIPSCCentury Therapeutics2.3479 of 5 stars$0.58+5.2%$5.00+756.6%-87.6%$49.63M$6.59M-0.32170Analyst ForecastGap DownITRMIterum Therapeutics1.8097 of 5 stars$1.43-0.7%$5.00+249.7%-23.8%$49.45MN/A-1.0910Positive NewsOTLKOutlook Therapeutics1.1091 of 5 stars$1.50-1.0%$10.20+582.3%-87.1%$48.35MN/A-0.2020Gap Down Remove Ads Related Companies and Tools Related Companies Virpax Pharmaceuticals Alternatives X4 Pharmaceuticals Alternatives Citius Oncology Alternatives VolitionRx Alternatives Aadi Bioscience Alternatives Werewolf Therapeutics Alternatives Immix Biopharma Alternatives Century Therapeutics Alternatives Iterum Therapeutics Alternatives Outlook Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
